LNP023 (Age-Related Macular Degeneration) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an investigational drug called JNJ-81201887 (the study drug) is a safe and effective option for people with geographic atrophy secondary to age-related macular degeneration.
Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD)
Who Can Participate in the Study?
Adults ages 50+ who:
- Are diagnosed with early or intermediate AMD
- Have not had eye surgery, including cataract surgery, within the last 3 months
- Have no active eye inflammation
For more information about who can be in this study, please contact the study team at DEC-RA@duke.edu.
What is Involved?
If you choose to join the study, you will:
- Get a random assignment (fair, equal chance) to 1 of 3 groups
-- One group will get a higher dose of the study drug
-- A second group will get a lower dose of the study drug
-- A third group will get a placebo (inactive substance)
- Visit our clinic at the Duke Eye Center up to 13 times.
- Keep in touch with the study team for about 19 months
At various visits, you will have blood draws, answer some questionnaires, and have eye exams and vision tests.